USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Genetic Therapy, Inc.
Address:
938 Clopper Road
Gaithersburg, MD 20878
Phone:
N/A
URL:
N/A
EIN:
N/A
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $341,163.00 5
SBIR Phase II $1,000,000.00 2

Award List:

GENERATION AND STUDY OF IL-1-SECRETING TIL CELLS

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$49,791.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

LIVER GROWTH FACTOR: GENE CLONING AND EXPRESSION

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$48,760.00
Agency:
HHS
Principal Investigator:
Paul Tolstoshev
Abstract:
The human cdna for hepatopoietin a will be isolated, using published sequence data, and will be inserted into a retroviral vector capable of expressing the gene in mammalian cells. the vector will be introduced into a variety of mammalian cells, including fibroblasts and hepatocytes, to measure the… More

RETROVIRAL VECTORS TO EXPRESS ALPHA-IFN IN HUMAN TIL

Award Year / Program / Phase:
1991 / SBIR / Phase I
Award Amount:
$44,900.00
Agency:
HHS
Principal Investigator:
Chiang, Yawen L , Principal Investigator
Abstract:
N/a

GENERATION AND STUDY OF IL-1-SECRETING TIL CELLS

Award Year / Program / Phase:
1993 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Abstract:
Conventional cancer treatments have been unable to eliminatemalignant cells in a significant number of cancer patients despite continute improvements in the clinical protocols utilized. adoptive immunotherapy with lymphokine-activated killer (lak) cells and ril-2 has provided an additional therapy… More

RETROVIRAL VECTORS TO EXPRESS ALPHA-IFN IN HUMAN TIL

Award Year / Program / Phase:
1993 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Chiang, Yawen L , Principal Investigator
Abstract:
Adoptive immunotherapy has provided an additional method of treating cancer. the use of lymphokine activated killer (lak) cells and in conjunction with interleukin-2 have shown remarkable results in some terminal cancer patients. recently ifn-a has been shown to have a synergistic effect in animal… More

Upregulaton of HSV TK Gene & Brain Cancer Gene Therapy

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$99,982.00
Agency:
HHS
Principal Investigator:
Yung-Nien Chang
Abstract:
We will test the capacity to increase tumor cell killing by introducing the herpes simplex virus (Hkinase (TK) gene on a retroviral vector and treating with ganciclovir (GCV). Our approach is to consthat can be upregulated to express elevated levels of HSV thymidine kinase. We will use… More

Targeting Adeno Vectors by Fiber Protein Engineering

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$97,730.00
Agency:
HHS
Principal Investigator:
Alan Mc Clelland
Abstract:
Our objective is to test the concept of engineering the fiber protein of adenovirus to target adenovectors via cell type specific receptors. Our approach is to modify the adenovirus fiber protein bydomain with ligands which bind to known cellular receptors which may be expressed in a cell… More